Kunal S Patel1, Sameer Kejriwal2, Michel M Sun3, Samasuk Thammachantha2, Courtney Duong1, Ann Chan3, Nina Cherian2, Prasanth Romiyo1, Lynn K Gordon3, William Yong2, Madhuri Wadehra2,4, Isaac Yang5,6,7. 1. Department of Neurosurgery, University of California, Los Angeles, CA, USA. 2. Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA. 3. Department of Ophthalmology, University of California, Los Angeles, CA, USA. 4. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA. 5. Department of Neurosurgery, University of California, Los Angeles, CA, USA. Iyang@mednet.ucla.edu. 6. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA. Iyang@mednet.ucla.edu. 7. Ronald Reagan UCLA Medical Center, David Geffen School of Medicine at UCLA, UCLA Jonsson Comprehensive Cancer Center, 300 Stein Plaza, Ste. 562, 5th Floor Wasserman Bldg., Los Angeles, CA, 90095-6901, USA. Iyang@mednet.ucla.edu.
Abstract
PURPOSE: Although intracranial meningiomas are the most common primary brain tumor in adults, treatment options are few and have traditionally been limited to surgical resection and radiotherapy. Additional targeted therapies and biomarkers are needed, especially as complete surgical resection is frequently not feasible in many patients. METHODS: Non-pathologic brain tissue from 3 patients undergoing routine autopsies and tumor specimens from 16 patients requiring surgical resection for meningioma were collected. EMP2 protein expression was evaluated by immunohistochemistry and western blot analysis. EMP2 mRNA expression was also investigated using surgical specimens and validated by analysis of several independent NCBI GEO databases. RESULTS: EMP2 mRNA expression levels were found to be higher in meningioma relative to non-pathologic meninges (P = 0.0013) and brain (P = 0.0011). Concordantly, strong EMP2 protein expression was demonstrated in 100% of meningioma specimens from all 16 patients, with no observable protein expression in normal brain tissue samples from 3 subjects (P < 0.001). EMP2 expression was confirmed by western blot analysis in five samples, with EMP2 protein intensity positively correlating with histologic staining score (R2 = 0.780; P = 0.047). No association was found between EMP2 mRNA or protein levels and WHO grade or markers of proliferation. However, EMP2 expression was positively associated with an angiomatous pattern on histologic evaluation (P = 0.0597), VEGF-A mRNA expression (P < 0.001), and clinical markers of tumor vascularity such as operative blood loss (P = 0.037). CONCLUSIONS: EMP2 is not found in normal brain tissue, yet has shown consistently high mRNA and protein expression in meningiomas, and may serve as a useful molecular marker for these tumors.
PURPOSE: Although intracranial meningiomas are the most common primary brain tumor in adults, treatment options are few and have traditionally been limited to surgical resection and radiotherapy. Additional targeted therapies and biomarkers are needed, especially as complete surgical resection is frequently not feasible in many patients. METHODS: Non-pathologic brain tissue from 3 patients undergoing routine autopsies and tumor specimens from 16 patients requiring surgical resection for meningioma were collected. EMP2 protein expression was evaluated by immunohistochemistry and western blot analysis. EMP2 mRNA expression was also investigated using surgical specimens and validated by analysis of several independent NCBI GEO databases. RESULTS:EMP2 mRNA expression levels were found to be higher in meningioma relative to non-pathologic meninges (P = 0.0013) and brain (P = 0.0011). Concordantly, strong EMP2 protein expression was demonstrated in 100% of meningioma specimens from all 16 patients, with no observable protein expression in normal brain tissue samples from 3 subjects (P < 0.001). EMP2 expression was confirmed by western blot analysis in five samples, with EMP2 protein intensity positively correlating with histologic staining score (R2 = 0.780; P = 0.047). No association was found between EMP2 mRNA or protein levels and WHO grade or markers of proliferation. However, EMP2 expression was positively associated with an angiomatous pattern on histologic evaluation (P = 0.0597), VEGF-A mRNA expression (P < 0.001), and clinical markers of tumor vascularity such as operative blood loss (P = 0.037). CONCLUSIONS:EMP2 is not found in normal brain tissue, yet has shown consistently high mRNA and protein expression in meningiomas, and may serve as a useful molecular marker for these tumors.
Authors: Christian Mawrin; Tina Sasse; Elmar Kirches; Siegfried Kropf; Thomas Schneider; Christoph Grimm; Claudia Pambor; Christian K Vorwerk; Raimund Firsching; Uwe Lendeckel; Knut Dietzmann Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: J Boström; B Meyer-Puttlitz; M Wolter; B Blaschke; R G Weber; P Lichter; K Ichimura; V P Collins; G Reifenberger Journal: Am J Pathol Date: 2001-08 Impact factor: 4.307
Authors: Maria Dolores Tabernero; Angel Maillo; Carlos J Gil-Bellosta; Abel Castrillo; Pablo Sousa; Marta Merino; Alberto Orfao Journal: Brain Pathol Date: 2008-07-15 Impact factor: 6.508
Authors: Andreas Keller; Nicole Ludwig; Christina Backes; Bernd F M Romeike; Nicole Comtesse; Wolfram Henn; Wolf-Ingo Steudel; Christian Mawrin; Hans-Peter Lenhof; Eckart Meese Journal: Int J Cancer Date: 2009-01-15 Impact factor: 7.396
Authors: Kunal S Patel; Sameer Kejriwal; Samasuk Thammachantha; Courtney Duong; Adrian Murillo; Lynn K Gordon; Timothy F Cloughesy; Linda Liau; William Yong; Isaac Yang; Madhuri Wadehra Journal: Neurooncol Adv Date: 2020-09-08